Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Moo-Kon | - |
dc.contributor.author | Chung, Joo-Seop | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Lim, Sung-Nam | - |
dc.contributor.author | Lee, Gyeong-won | - |
dc.contributor.author | Choi, Jae-Cheol | - |
dc.contributor.author | Park, Won-Young | - |
dc.contributor.author | Oh, So-Yeon | - |
dc.date.accessioned | 2022-07-14T20:37:41Z | - |
dc.date.available | 2022-07-14T20:37:41Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/153066 | - |
dc.description.abstract | Tumor necrosis (TN) can lower responsiveness to chemotherapy and confer basic resistance to anti-cancer therapy. We investigated the association of TN with poor clinical features and outcome in diffuse large B cell lymphoma (DLBCL). We examined the presence or absence of TN in 476 DLBCL patients of who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Eighty-nine (18.7 %) patients had TN at diagnosis. Patients with TN had a progression-free survival (PFS) and overall survival (OS) of 39.3 and 46.7 %, whereas patients without TN had a PFS and OS of 73.4 and 82.6 %. Adverse clinical factors of poor Eastern Cooperative Oncology Group performance status ≥ grade 2 (p = 0.005), elevated lactate dehydrogenase ratio >1 (p < 0.001), advanced Ann Arbor stage (p = 0.002), and bulky disease (p = 0.026) were more prevalent in the TN group than the non-TN group. Cox regression model analysis revealed TN as an independent prognostic factor for PFS and OS in DLBCL (PFS, hazard ratio [HR] = 1.967, 95 % confidence interval [CI] = 1.399–2.765, p < 0.001; OS, HR = 2.445, 95 % CI = 1.689–3.640, p < 0.001). The results indicate that TN could reflect adverse clinical features and worse prognosis in DLBCL patients receiving R-CHOP therapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.title | Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Moo-Kon | - |
dc.identifier.doi | 10.1007/s00277-016-2822-8 | - |
dc.identifier.scopusid | 2-s2.0-84988737056 | - |
dc.identifier.wosid | 000391365100003 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.96, no.1, pp.17 - 23 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 96 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 17 | - |
dc.citation.endPage | 23 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | RITUXIMAB ERA | - |
dc.subject.keywordPlus | PREDICTOR | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | IPI | - |
dc.subject.keywordPlus | CT | - |
dc.subject.keywordAuthor | Tumor necrosis | - |
dc.subject.keywordAuthor | Diffuse large B cell lymphoma | - |
dc.subject.keywordAuthor | Ann Arbor stage | - |
dc.subject.keywordAuthor | Survival | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00277-016-2822-8 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.